Abstract 038: Association of Circulating Metabolites with Incident Heart Failure and its Subtypes in Multi-ethnic Populations
Abstract
Introduction: Metabolic dysregulation is recognized in heart failure (HF). A comprehensive assessment of circulating metabolites, specifically on HF subtypes, in multi-ethnic populations is limited. Hypothesis: We hypothesize that circulating metabolites are significantly associated with the risk of HF and have differential effects on HF subtypes. Methods: Circulating metabolites from seven studies in the Trans-Omics for Precision Medicine Program were analyzed among 21,398 HF-free participants (58% non-Whites, 58% women), from which 1,160 incident HF, 373 HF with reduced (HFrEF), and 439 HF with preserved ejection fraction (HFpEF) events were ascertained with an average of 11.5 years of follow up. Cox proportional hazard regressions were applied by the study, followed by random-effect meta-analyses, to produce metabolite HF associations. Over-representation analyses were performed to identify relevant metabolite pathways. Results: Out of 1,015 metabolites analyzed, 54 were significantly associated with incident HF (Bonferroni corrected p<0.05) after accounting for clinical risk factors. Eleven metabolic pathways were mapped; pentose and glucuronate interconversions and pyrimidine metabolism demonstrated over-representation (FDR<0.05). Most identified metabolites (93%) were positively associated with HF, and the strength of the associations persisted with further adjustment of kidney function. Thirteen metabolites showed consistent effects from all participating studies, and subtype analyses indicated that most metabolites were more strongly associated with HFpEF than HFrEF ( Figure ). For example, N-acetylputrescine, a precursor of γ-aminobutyric acid (GABA), and 4-acetamidobutanoate, a derivative of GABA, were associated with an increased risk of HFpEF but not HFrEF. Conclusions: We identified circulating metabolites associated with the risk of HF in multi-ethnic populations, highlighting the need to better understand the differential metabolic etiology of HFpEF compared to HFrEF.
Article Details
Authors (23)
Eun Hye Moon
UTHealth at Houston, Houston, Texas, United States
Taryn Alkis
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Kai Luo
Megan Grove
UTHealth, Houston, Texas, United States
Eric Boerwinkle
Clary Clish
Robert Gerszten
Michael and Jo Alice Hall
University of Mississippi Medical Center, Jackson, Mississippi, United States
Lifang Hou
Scott Hutton
Metabolon, Inc, Morrisville, North Carolina, United States
Robert Kaplan
Donald Lloyd-Jones
Framingham Center for Population and Prevention Science, Framingham, MA
Bruce Psaty
University of Washington, Seattle, WA, USA.
Laura Raffield
Carlos Rodriguez
Jerome Rotter
The Lundquist Institute, Torrance, California, United States
Amil Shah
University of Texas Southwestern Medical Center, Dallas (A.S.).
Sanjiv Shah
Northwestern University Feinberg School of Medicine, Chicago
Kent Taylor
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
Kari Wong
Vanessa Xanthakis
Vasan Ramachandran
The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States
Bing Yu
College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry